Research method for promoting ulcerative colitis barrier repair mechanism by activating intestinal epithelial autophagy through butyric acid
By activating the ATG16L1-related autophagy pathway, butyrate promotes UC barrier repair, offering a new treatment approach with improved efficacy and reduced side effects.
Patent Information
- Application Number
- CN202411209658.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for ulcerative colitis (UC) rely on anti-inflammatory drugs with limited efficacy, significant side effects, and high recurrence rates, while the mechanism of butyrate in promoting intestinal epithelial autophagy for barrier repair is not fully understood.
A research method involving clinical sample analysis, animal model experiments, and cell experiments to elucidate how butyrate activates the ATG16L1-related autophagy pathway, improving intestinal epithelial barrier function and inflammation in UC.
Reveals a new mechanism for UC barrier repair, potentially leading to more effective, personalized treatments with lower side effects and recurrence rates, and provides a theoretical basis for developing new therapeutic drugs.
Smart Images

Figure CN119061105A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to digestive system technology, and in particular to a research method for promoting the barrier repair mechanism of ulcerative colitis by activating intestinal epithelial autophagy using butyrate. Background Art
[0002] With the development of urbanization and industrialization, the incidence of IBD has shown a clear upward trend in my country. According to the data of the Chinese Center for Disease Control and Prevention in the past ten years, it is estimated that the number of IBD patients in my country will reach 1.5 million in 2025, among which ulcerative colitis (UC) has significant clinical symptoms. With the popularization of gastrointestinal endoscopy, the diagnosis rate of UC has also increased year by year. UC is a chronic nonspecific intestinal inflammatory disease with a complex pathogenesis involving multiple factors such as genetics, immunity, environment and intestinal microecology. UC patients often show impaired intestinal barrier function, persistent inflammatory response and decreased intestinal autophagy. These pathological and physiological processes are interrelated and jointly promote the occurrence and development of the disease. At present, the clinical treatment of UC mainly relies on anti-inflammatory drugs and immunosuppressants, but these drugs have problems such as limited efficacy, large side effects and high recurrence rate.
[0003] At present, there are many studies on butyrate and the clinical phenotype of UC. The specific mechanism of butyrate in UC is mainly discussed around the inhibition of histone deacetylase in the intestinal mucosa to play an anti-inflammatory role. However, there are few studies on the mechanism of butyrate around autophagy. Butyrate, as an important microbiota metabolite, plays an important role in the diagnosis and treatment of UC, especially the treatment method with microbiota as the core has a special marker function. The intestine is an important barrier environment for the human body, and there is also a complex microecological system. The metabolites of intestinal flora always affect the bacteria, intestinal epithelial cells, mucosa and immune status in the intestinal cavity. Intestinal barrier function is an important part of innate immunity. Studies have shown that butyrate can activate the ATG16L1-dependent autophagy pathway, thereby improving intestinal inflammation and barrier function. However, the detailed mechanism of how butyrate promotes UC barrier repair through the ATG16L1-related autophagy mechanism is not yet fully understood. Summary of the invention
[0004] The purpose of the present invention is to provide a research method for promoting the barrier repair mechanism of ulcerative colitis by activating intestinal epithelial autophagy using butyrate, so as to solve the above-mentioned deficiencies in the prior art.
[0005] In order to achieve the above object, the present invention provides the following technical solution: a research method for promoting the barrier repair mechanism of ulcerative colitis by activating intestinal epithelial autophagy using butyrate, comprising the following steps:
[0006] S1. Clinical sample collection and analysis: Colonoscopic biopsy tissue and stool samples were collected, and the fecal SCFAs content was determined by targeted LC-MS. IHC, IF, WB and PCR were used to detect the expression of corresponding proteins, and the correlation between fecal butyrate, UC disease severity, corresponding protein autophagy expression and epithelial barrier was analyzed;
[0007] S2. Animal model construction and experiments: DSS / TNBS-induced enteritis mice were constructed to observe the effects of butyrate on enteritis, autophagy and intestinal epithelial barrier. Rapamycin or hydroxychloroquine was used to construct enteritis mice with autophagy activation or inhibition to observe the effects of autophagy activation on enteritis. Butyrate was given to intervene in autophagy inhibition of enteritis mice to observe whether butyrate activates ATG16L1-related autophagy to improve enteritis and intestinal epithelial barrier. ATG16L1 was used to inhibit enteritis. △IEC Conditional knockout mice or si-ATG16L1-RNA interference technology, combined with DSS / TNBS-induced enteritis model, to observe the role of ATG16L1 in enteritis and intestinal epithelial barrier, and to observe the effect of butyrate intervention. Finally, the in vivo experimental results were analyzed to clarify the regulatory relationship and rules of butyrate, ATG16L1, autophagy and intestinal barrier.
[0008] S3. Cell experiment verification: TNF-α / LPS were used to construct the Caco2 / HcoEp i C / NCM460 inflammatory intestinal barrier model, and the expression of corresponding proteins was detected after butyrate intervention. The cells were transfected with ATG16L1 overexpression plasmid and RNA interference plasmid to observe the effect of ATG16L1 on enteritis under inflammatory conditions, and to verify whether butyrate can activate ATG16L1-related autophagy to improve enteritis and intestinal epithelial barrier. Finally, the regulatory relationship and rules of butyrate, ATG16L1, autophagy and intestinal barrier were observed.
[0009] Furthermore, the corresponding proteins include ATG16L1, P62, MTOR, p-MTOR, LC3 II / I, ZO-1 and Occludine.
[0010] Furthermore, the expression of corresponding proteins in S3 after butyrate intervention was detected by observing the morphology of autophagosomes under an electron microscope, detecting the transepithelial electrical resistance TEER value and fluorescent yellow transmittance, and using ICC, WB and PCR techniques to detect the expression of corresponding proteins.
[0011] Furthermore, using ATG16L1 △IEC The specific experimental groups of conditional knockout mice combined with the DSS / TNBS-induced enteritis model were as follows: normal control group, ATG16L1△I EC control group, DSS enteritis group, ATG16L1△I EC+DSS enteritis group, and ATG16L1△I EC+DSS / TNBS+Butyrate treatment group;
[0012] The specific experimental groups of the DSS / TNBS-induced enteritis model using si-ATG16L1-RNA interference technology are as follows: normal control group, si-ATG16L1-RNA control group, DSS / TNBS enteritis group, si-ATG16L1-RNA enteritis group, and si-ATG16L1-RNA+DSS / TNBS+Butyrate treatment group.
[0013] Furthermore, the plasmid-transfected cells are plasmid-transfected Caco2 / HcoEp i C / NCM460 cells.
[0014] Furthermore, S2 observed the role of ATG16L1 in enteritis and intestinal epithelial barrier, and observed the effect of butyrate intervention, as follows:
[0015] DAI, colon length, colon macroscopy and colon pathology were observed, and ELISA was used to detect the levels of inflammatory factors TNF-α, IL-6 and IL-1β.
[0016] FI TC-dextran intestinal permeability test, IF, WB and PCR detection of tight junction proteins;
[0017] Autophagosomes were observed under electron microscopy, ATG16L1, P62, MTOR, p-MTOR and LC3 II / I were detected by I HC, WB and PCR, and the intestinal barrier structure was observed under electron microscopy.
[0018] Furthermore, the Caco2 / HcoEp i C / NCM460 inflammatory intestinal barrier model was constructed using TNF-α / LPS.
[0019] The model was constructed using a human colon cancer epithelial cell line Caco2 and two normal human colon epithelial cell lines HcoEp i C and NCM460.
[0020] Furthermore, in S3, the effect of ATG16L1 on enteritis under inflammatory conditions was observed by detecting the expression of inflammatory factors TNF-α, IL-6 and IL-1β using WB, PCR and ELISA.
[0021] Furthermore, the DSS model construction method is as follows:
[0022] The enteritis mouse model was established by continuous drinking water administration of 3% DSS for 7 days. The mice were weighed daily, and the stool characteristics and occult blood content were measured. The occult blood content in the feces was detected using an occult blood reagent.
[0023] Furthermore, the TNBS model construction method is as follows:
[0024] a. A 7-day enteritis model was used. On the first day of the experiment, mice were anesthetized by intraperitoneal injection of sodium pentobarbital at a dose of 40 mg / kg, 0.1 mL / 10 g body weight. A rubber tube was gently inserted into the mouse through the anus about 3 cm into the mouse body. A 25 mg / L TNBS solution was slowly injected into the mouse intestinal cavity through the anus at a dose of 0.1 mL / mouse with a syringe. After the administration was completed, the plastic tube was slowly pulled out, the mouse tail was lifted, and it was kept inverted for 1 min to allow the modeling drug to fully penetrate into the mouse intestinal cavity.
[0025] b. Weigh the mice daily and test fecal occult blood using an occult blood test kit;
[0026] c. Give 0.2 g / kg of sodium butyrate solution by gavage every day, 0.1 mL / 10 g body weight, for a total of 7 days;
[0027] d. On the morning of the 8th day, weigh the mice, and measure the stool characteristics and occult blood content. After testing the fecal occult blood content with a fecal occult blood reagent, kill the mice for sample collection.
[0028] Compared with the prior art, the present invention provides a research method for the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate. By systematically studying the effects of butyrate on intestinal epithelial autophagy and barrier function in UC patients and animal models, a new mechanism is revealed in which butyrate promotes UC barrier repair by activating the ATG16L1-related autophagy pathway, which provides a new theoretical basis for the treatment of UC.
[0029] In-depth research on the regulatory mechanism of butyrate on ATG16L1-related autophagy will help achieve accurate diagnosis and personalized treatment of UC, that is, choosing the appropriate treatment plan according to the patient's specific situation to improve the treatment effect and reduce unnecessary medical expenses. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present invention. For ordinary technicians in this field, other drawings can also be obtained based on these drawings.
[0031] Figure 1 A schematic diagram of the process of clinical sample collection and analysis provided by an embodiment of the present invention;
[0032] Figure 2 A schematic diagram of the process of constructing an animal model and conducting an experiment provided in an embodiment of the present invention;
[0033] Figure 3 A schematic diagram of the process of cell experiment verification provided by an embodiment of the present invention;
[0034] Figure 4 A schematic diagram of the correlation between fecal butyric acid content and enteritis symptoms in fecal microbiota transplantation treatment provided in an embodiment of the present invention;
[0035] Figure 5 A schematic diagram showing that butyrate provided in an embodiment of the present invention effectively improves symptoms and indicators related to enteritis in UC mice;
[0036] Figure 6 Schematic diagram of butyrate effectively improving barrier damage in UC mice provided by an embodiment of the present invention;
[0037] Figure 7 A schematic diagram of the combined omics analysis of butyrate-treated UC mice provided in an embodiment of the present invention;
[0038] Figure 8 A schematic diagram of butyrate upregulating ATG16L1-related autophagy expression in UC mice provided in an embodiment of the present invention;
[0039] Fig. 9 A schematic diagram of butyrate provided in an embodiment of the present invention showing that it exerts therapeutic effects by upregulating ATG16L1-related autophagy. DETAILED DESCRIPTION
[0040] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be further described in detail below with reference to the accompanying drawings.
[0041] See also Figures 1 to 9 , a research method for using butyrate to activate intestinal epithelial autophagy to promote the barrier repair mechanism of ulcerative colitis, the following steps:
[0042] S1. Clinical sample collection and analysis: Colonoscopic biopsy tissue and stool samples were collected, and 60 clinically diagnosed UC patients and 30 healthy volunteers were enrolled as research subjects. UC patients recorded relevant indicators (clinical symptoms, blood routine, procalcitonin, C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, etc.) and performed Mayo score. Healthy volunteers were selected from those with similar age, gender, and living area. Before enrollment, UC patients and healthy volunteers were required to have colonoscopy results within 6 months to clarify the intestinal status. Qualified patients were required to retain stool samples (which could be transferred to a -80℃ refrigerator within 30 minutes for subsequent SCFAs detection). Colonoscopy was performed at an elective time, and intestinal mucosal tissue was obtained with biopsy forceps for subsequent experiments. The fecal SCFAs content was determined by LC-MS, and the expression of corresponding proteins was detected by IHC, IF, WB and PCR. The corresponding proteins included ATG16L1, P62, MTOR, p-MTOR, LC3 II / I, ZO-1 and Occlud in, a piece of biopsy tissue was retained for paraffin embedding and HE staining. When conditions permit, intestinal tissue transmission electron microscopy was performed as much as possible to observe autophagosomes and barrier structures, and to analyze the correlation between fecal butyrate, UC disease severity, corresponding protein autophagy expression, and epithelial barrier;
[0043] S2. Animal model construction and experiments: DSS / TNBS-induced enteritis mice were constructed to observe the effects of butyrate on enteritis, autophagy and intestinal epithelial barrier. Rapamycin or hydroxychloroquine was used to construct enteritis mice with autophagy activation or inhibition to observe the effects of autophagy activation on enteritis. Butyrate was given to intervene in autophagy inhibition of enteritis mice to observe whether butyrate activates ATG16L1-related autophagy to improve enteritis and intestinal epithelial barrier. ATG16L1 was used to inhibit enteritis. △IEC Conditional knockout mice or si-ATG16L1-RNA interference technology combined with DSS / TNBS-induced enteritis model;
[0044] Utilizing ATG16L1 △IEC The specific experimental groups of conditional knockout mice combined with the DSS / TNBS-induced enteritis model were as follows: normal control group, ATG16L1△I EC control group, DSS enteritis group, ATG16L1△I EC+DSS enteritis group, and ATG16L1△I EC+DSS / TNBS+Butyrate treatment group;
[0045] The specific experimental groups of the DSS / TNBS-induced enteritis model using si-ATG16L1-RNA interference technology were as follows: normal control group, si-ATG16L1-RNA control group, DSS / TNBS enteritis group, si-ATG16L1-RNA enteritis group, and si-ATG16L1-RNA+DSS / TNBS+Butyrate treatment group;
[0046] Observe the role of ATG16L1 in enteritis and intestinal epithelial barrier, as follows:
[0047] DAI, colon length, colon macroscopy and colon pathology were observed, and ELISA was used to detect the levels of inflammatory factors TNF-α, IL-6 and IL-1β.
[0048] FI TC-dextran intestinal permeability test, IF, WB and PCR detection of tight junction proteins;
[0049] Observe the effect of butyrate intervention, that is, observe whether butyrate can activate ATG16L1-related autophagy and thus improve enteritis and intestinal epithelial barrier, as follows:
[0050] Autophagosomes were observed by electron microscopy, ATG16L1, P62, MTOR, p-MTOR and LC3 II / I were detected by I HC, WB and PCR, and the intestinal barrier structure was observed by electron microscopy;
[0051] Finally, the in vivo experimental results were analyzed to clarify the regulatory relationship and rules among butyrate, ATG16L1, autophagy and intestinal barrier;
[0052] The DSS model construction method is as follows:
[0053] The enteritis mouse model was established by continuous drinking water administration of 3% DSS for 7 days. The mice were weighed daily, and the stool characteristics and occult blood content were measured. The occult blood content in the feces was detected using an occult blood reagent.
[0054] The TNBS model was constructed as follows:
[0055] a. A 7-day enteritis model was used. On the first day of the experiment, mice were anesthetized by intraperitoneal injection of sodium pentobarbital at a dose of 40 mg / kg, 0.1 mL / 10 g body weight. A rubber tube was gently inserted into the mouse through the anus about 3 cm into the mouse body. A 25 mg / L TNBS solution was slowly injected into the mouse intestinal cavity through the anus at a dose of 0.1 mL / mouse with a syringe. After the administration was completed, the plastic tube was slowly pulled out, the mouse tail was lifted, and it was kept inverted for 1 min to allow the modeling drug to fully penetrate into the mouse intestinal cavity.
[0056] b. Weigh the mice daily and test fecal occult blood using an occult blood test kit;
[0057] c. Give 0.2 g / kg of sodium butyrate solution by gavage every day, 0.1 mL / 10 g body weight, for a total of 7 days;
[0058] d. On the morning of the 8th day, weigh the mice, and measure the stool characteristics and occult blood content. After testing the fecal occult blood content with a fecal occult blood reagent, kill the mice for sample collection.
[0059] S3. Cell experiment verification: TNF-α / LPS was used to construct the Caco2 / HcoEp i C / NCM460 inflammatory intestinal barrier model. A human colon cancer epithelial cell line Caco2 and two normal human colon epithelial cells HcoEp i C and NCM460 were used to construct the model. The expression of corresponding proteins was detected after butyrate intervention. The morphology of autophagosomes was observed by electron microscopy, the transepithelial electrical resistance TEER value and fluorescent yellow transmittance were detected, and the expression of corresponding proteins was detected by ICC, WB and PCR techniques. The cells were transfected with ATG16L1 overexpression plasmid and RNA interference plasmid. The plasmid-transfected cells were plasmid-transfected Caco2 / HcoEp iC / NCM460 cells. The effect of ATG16L1 on enteritis under inflammatory state was observed. WB, PCR and ELISA were used to detect the inflammatory factors TNF-α, IL-6 and I The expression of L-1β was detected and verified whether butyrate could activate ATG16L1-related autophagy to improve enteritis and intestinal epithelial barrier. The specific groups were as follows: normal group, TNF-α / LPS group, TNF-α / LPS+overexpression ATG16L1 group, TNF-α / LPS+knockdown ATG16L1 group, TNF-α / LPS+Butyrate group, TNF-α / LPS+knockdown ATG16L1+Butyrate group. Finally, the regulatory relationship and rules of butyrate, ATG16L1, autophagy and intestinal barrier were observed.
[0060] Figure 4 In the figure, A: The fecal butyric acid content of UC patients in the effective response stage was significantly increased compared with that before treatment; B: The fecal butyric acid content of DSS-induced enteritis mice was significantly reduced compared with the control group. After human or mouse microbiota treatment, the fecal butyric acid content was significantly increased compared with the enteritis model group; C: The Mayo score of UC patients was negatively correlated with the fecal butyric acid content; D: In the mouse experiment, the mouse disease activity (DAI) was negatively correlated with the fecal butyric acid content. (*P<0.05, **P<0.01).
[0061] Figure 5 A: DAI of DSS-induced UC mice increased significantly compared with the control group, and DAI was significantly reduced after butyrate treatment; B: DSS caused a significant shortening of the colon length of mice, and the shortening of the colon of UC mice was significantly improved after butyrate treatment; C&D: Compared with the control group, the colon epithelium of UC mice was severely damaged, with a lack of epithelial cells, incomplete glands, and severe neutrophil infiltration. The above pathological changes were significantly improved after sodium butyrate intervention; E: The serum inflammatory factors TNF-α, IL-6, and IL-1β of UC mice were significantly increased compared with the control group, and the three serum inflammatory factors were significantly reduced after butyrate treatment. (*P<0.05, **P<0.01, ***P<0.001).
[0062] Figure 6 Middle, A, B&C: Colon I HC showed that tight junction proteins ZO-1 and Occludin were significantly decreased in DSS-induced UC mice, and ZO-1 and Occludin were significantly increased after butyrate treatment; D, E&F: Colon I HC showed that tight junction proteins ZO-1 and Occludin were significantly decreased in DSS-induced UC mice, and ZO-1 and Occludin were significantly increased after butyrate treatment. (*P<0.05, **P<0.01, ***P<0.001).
[0063] Figure 7 In the figure, A&B: Colon tissue RNA-seq found differentially expressed genes in the butyrate group vs. the enteritis model group and found the top 20 enriched signal pathways through KEGG enrichment analysis; C&D: LC-MS method was used to determine serum non-targeted metabolites, and a total of 342 differential metabolites were found under positive and negative ion states; E: Metabolome-transcriptome association analysis found 4 differentially associated signal pathways, among which autophagy ranked first.
[0064] Figure 8 In the experiment, the autophagy proteins such as P62, MTOR, p-MTOR, LC3 II / I and ATG16L1 were detected by WB. The grayscale analysis results showed that the content of the above autophagy proteins in DSS-induced enteritis mice was significantly changed, showing an autophagy inhibition state, while the autophagy level in the butyrate treatment group increased to varying degrees. (*P<0.05, **P<0.01).
[0065] Fig. 9 In this study, rapamycin (RAPA) / hydroxychloroquine (CQ) combined with DSS-induced enteritis was used to construct autophagy-activated / inhibited UC mice, and the effect of butyrate was preliminarily observed by upregulating ATG16L1-related autophagy. Autophagy activation improved DAI (A), colon shortening (B&C), and colon pathological damage (D) in UC mice. Butyrate may exert its therapeutic effect by activating autophagy. The expression of autophagy proteins in each group was further detected by WB, indicating that butyrate may exert its therapeutic effect through ATG16L1-related autophagy. (*P<0.05, **P<0.01,
[0066] ***P<0.001).
[0067] Revealing the new mechanism of butyrate in the treatment of UC: This paper systematically studies the effects of butyrate on intestinal epithelial autophagy and barrier function in UC patients and animal models, and reveals a new mechanism by which butyrate promotes UC barrier repair by activating the ATG16L1-related autophagy pathway, providing a new theoretical basis for the treatment of UC.
[0068] Improving the therapeutic effect of UC: The new mechanism of butyrate-activated autophagy will help promote the development of new UC therapeutic drugs based on butyrate or its analogs. These drugs may have higher efficacy, lower side effects and lower recurrence rate, thereby improving the quality of life of UC patients.
[0069] Promoting intestinal health research: The research method of the present invention is not limited to UC, but can also be extended to the research of other intestinal inflammatory diseases and diseases related to intestinal microecological imbalance, providing new perspectives and ideas for intestinal health research.
[0070] Promote the development of precision medicine: In-depth research on the regulatory mechanism of butyrate on ATG16L1-related autophagy will help achieve accurate diagnosis and personalized treatment of UC, that is, to select appropriate treatment plans according to the specific conditions of patients, so as to improve treatment effects and reduce unnecessary medical expenses.
[0071] The effects of butyrate on ATG16L1-related autophagy were verified by using a combination of ATG16L1△I EC conditional knockout mice, overexpression and RNA interference, intestinal barrier morphology / function / gene expression, etc., to elucidate the possible mechanisms and rules by which butyrate promotes intestinal barrier repair through ATG16L1 and prevents the progression of UC, providing a new theory and clinical application basis for protecting intestinal flora metabolites and preventing intestinal diseases related to intestinal barrier imbalance.
[0072] In summary, the above research methods not only enrich the theoretical system of UC pathogenesis, but also provide new strategies and ideas for the treatment of UC, which has important scientific value and social significance.
[0073] The above description is only by way of illustration of certain exemplary embodiments of the present invention. It is undoubted that those skilled in the art can modify the described embodiments in various ways without departing from the spirit and scope of the present invention. Therefore, the above drawings and descriptions are illustrative in nature and should not be construed as limiting the scope of protection of the claims of the present invention.
Claims
1. A research method for promoting the barrier repair mechanism of ulcerative colitis by activating intestinal epithelial autophagy using butyrate, characterized in that: The steps include: S1. Clinical sample collection and analysis: Colonoscopic biopsy tissue and stool samples were collected, and the fecal SCFAs content was determined by targeted LC-MS. IHC, IF, WB and PCR were used to detect the expression of corresponding proteins, and the correlation between fecal butyrate, UC disease severity, corresponding protein autophagy expression and epithelial barrier was analyzed; S2. Animal model construction and experiments: DSS / TNBS-induced enteritis mice were constructed to observe the effects of butyrate on enteritis, autophagy and intestinal epithelial barrier. Rapamycin or hydroxychloroquine was used to construct enteritis mice with autophagy activation or inhibition to observe the effects of autophagy activation on enteritis. Butyrate was given to intervene in autophagy inhibition of enteritis mice to observe whether butyrate activates ATG16L1-related autophagy to improve enteritis and intestinal epithelial barrier. ATG16L1 was used to inhibit enteritis. △IEC Conditional knockout mice or si-ATG16L1-RNA interference technology, combined with DSS / TNBS-induced enteritis model, to observe the role of ATG16L1 in enteritis and intestinal epithelial barrier, and to observe the effect of butyrate intervention, and to analyze the in vivo experimental results to clarify the regulatory relationship and rules of butyrate, ATG16L1, autophagy and intestinal barrier; S3. Cell experiment verification: TNF-α / LPS were used to construct the Caco2 / HcoEp i C / NCM460 inflammatory intestinal barrier model, and the expression of corresponding proteins was detected after butyrate intervention. The cells were transfected with ATG16L1 overexpression plasmid and RNA interference plasmid to observe the effect of ATG16L1 on enteritis under inflammatory conditions, and to verify whether butyrate can activate ATG16L1-related autophagy to improve enteritis and intestinal epithelial barrier. Finally, the regulatory relationship and rules of butyrate, ATG16L1, autophagy and intestinal barrier were observed.
2. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: The corresponding proteins include ATG16L1, P62, MTOR, p-MTOR, LC3 II / I, ZO-1 and Occludin.
3. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: In S3, the expression of corresponding proteins after butyrate intervention was detected by observing the morphology of autophagosomes under an electron microscope, detecting the transepithelial electrical resistance TEER value and fluorescent yellow transmittance, and using ICC, WB and PCR techniques to detect the expression of corresponding proteins.
4. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: Utilizing ATG16L1 △IEC The specific experimental groups of conditional knockout mice combined with the DSS / TNBS-induced enteritis model are as follows: normal control group, ATG16L1△IEC control group, DSS enteritis group, ATG16L1△IEC+DSS enteritis group, and ATG16L1△IEC+DSS / TNBS+Butyrate treatment group; The specific experimental groups using si-ATG16L1-RNA interference technology combined with the DSS / TNBS-induced enteritis model are as follows: normal control group, si-ATG16L1-RNA control group, DSS / TNBS enteritis group, si-ATG16L1-RNA enteritis group, and si-ATG16L1-RNA+DSS / TNBS+Butyrate treatment group.
5. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: Plasmid transfected cells are plasmid transfected Caco2 / HcoEpiC / NCM460 cells.
6. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: S2 observed the role of ATG16L1 in enteritis and intestinal epithelial barrier, and observed the effects of butyrate intervention, as follows: DAI, colon length, colon macroscopy and colon pathology were observed, and the levels of inflammatory factors TNF-α, IL-6 and IL-1β were detected by ELISA; FI TC-dextran intestinal permeability test, IF, WB and PCR detection of tight junction proteins; Autophagosomes were observed under electron microscopy, ATG16L1, P62, MTOR, p-MTOR and LC3 II / I were detected by I HC, WB and PCR, and the intestinal barrier structure was observed under electron microscopy.
7. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: The specific steps of constructing the Caco2 / HcoEpiC / NCM460 inflammatory intestinal barrier model using TNF-α / LPS are as follows: The model was constructed using a human colon cancer epithelial cell line Caco2 and two normal human colon epithelial cell lines HcoEpi C and NCM460.
8. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: In S3, the effect of ATG16L1 on enteritis under inflammatory conditions was observed, and the expression of inflammatory factors TNF-α, IL-6 and IL-1β was detected by WB, PCR and ELISA.
9. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: The DSS model construction method is as follows: The enteritis mouse model was established by continuous drinking water administration of 3% DSS for 7 days. The mice were weighed daily, and the stool characteristics and occult blood content were measured. The occult blood content in the feces was detected using an occult blood reagent.
10. The method for studying the mechanism of promoting barrier repair of ulcerative colitis by activating intestinal epithelial autophagy using butyrate according to claim 1, characterized in that: The TNBS model was constructed as follows: a. A 7-day enteritis model was used. On the first day of the experiment, mice were anesthetized by intraperitoneal injection of sodium pentobarbital at a dose of 40 mg / kg, 0.1 mL / 10 g body weight. A rubber tube was gently inserted into the mouse through the anus about 3 cm into the mouse body. A 25 mg / L TNBS solution was slowly injected into the mouse intestinal cavity through the anus at a dose of 0.1 mL / mouse with a syringe. After the administration was completed, the plastic tube was slowly pulled out, the mouse tail was lifted, and it was kept inverted for 1 min to allow the modeling drug to fully penetrate into the mouse intestinal cavity. b. Weigh the mice daily and test fecal occult blood using an occult blood test kit; c. Give 0.2 g / kg of sodium butyrate solution by gavage every day, 0.1 mL / 10 g body weight, for a total of 7 days; d. On the morning of the 8th day, weigh the mice, and measure the stool characteristics and occult blood content. After testing the fecal occult blood content with a fecal occult blood reagent, kill the mice for sample collection.
Citation Information
Patent Citations
Application of clinacanthus nutans extract in preparation of medicine for preventing or treating ulcerative colitis
CN117414379A
Treatment of autophagy-related disorders
WO2014200705A1
Method for screening inflammatory bowel disease therapeutic agent targeting RORα
WO2021091009A1
